Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GPCR Structure Therapeutics	$18.82 +1.3%	$19.16	$13.22 ▼ $45.37	$1.07B	-1.89	900,051 shs	424,017 shs
PHVS Pharvaris	$24.00 +1.5%	$20.55	$11.51 ▼ $26.33	$1.24B	-2.81	109,730 shs	323,333 shs
RNAC Cartesian Therapeutics	$10.78 -4.2%	$11.71	$8.46 ▼ $26.50	$292.52M	0.44	54,128 shs	44,816 shs
TLRY Tilray Brands	$1.45 +4.3%	$0.70	$0.35 ▼ $1.88	$1.53B	1.85	82.49 million shs	142.87 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GPCR Structure Therapeutics	+1.35%	+0.11%	+4.91%	-15.23%	-53.65%
PHVS Pharvaris	+1.48%	+3.18%	+16.39%	+55.24%	+25.79%
RNAC Cartesian Therapeutics	-4.18%	-0.65%	-19.13%	+18.59%	-23.05%
TLRY Tilray Brands	+4.32%	+36.79%	+110.60%	+222.44%	-22.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GPCR Structure Therapeutics	2.8411 of 5 stars	3.5	3.0	2.9	1.7	0.6
PHVS Pharvaris	2.7445 of 5 stars	3.4	4.0	2.8	0.0	0.0
RNAC Cartesian Therapeutics	2.516 of 5 stars	3.4	2.0	2.7	3.3	0.0
TLRY Tilray Brands	1.8778 of 5 stars	3.2	1.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GPCR Structure Therapeutics	3.00	Buy	$75.71	302.31% Upside
PHVS Pharvaris	2.83	Moderate Buy	$35.60	48.33% Upside
RNAC Cartesian Therapeutics	2.80	Moderate Buy	$40.00	271.06% Upside
TLRY Tilray Brands	2.33	Hold	$1.94	33.62% Upside

Current Analyst Ratings Breakdown

Latest RNAC, PHVS, GPCR, and TLRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	TLRY Tilray Brands	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1.50 ➝ $2.00
8/18/2025	PHVS Pharvaris	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/13/2025	PHVS Pharvaris	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$55.00 ➝ $52.00
8/7/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $60.00
8/7/2025	GPCR Structure Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$92.00 ➝ $90.00
8/7/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$89.00 ➝ $87.00
7/29/2025	TLRY Tilray Brands	Zelman & Associates Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
7/9/2025	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
6/11/2025	PHVS Pharvaris	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$32.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$13.40 per share	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	$4.00 per share	N/A
RNAC Cartesian Therapeutics	$38.91M	7.20	N/A	N/A	($0.10) per share	-107.80
TLRY Tilray Brands	$821.31M	1.94	$0.15 per share	9.62	$1.40 per share	1.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GPCR Structure Therapeutics	-$122.53M	-$1.05	N/A	N/A	N/A	N/A	-21.31%	-20.34%	11/12/2025 (Estimated)
PHVS Pharvaris	-$145.24M	-$3.36	N/A	N/A	N/A	N/A	-69.09%	-63.34%	11/12/2025 (Estimated)
RNAC Cartesian Therapeutics	-$77.42M	-$52.83	N/A	N/A	N/A	N/A	N/A	-6.36%	11/6/2025 (Estimated)
TLRY Tilray Brands	-$2.19B	-$2.31	N/A	N/A	N/A	-265.69%	-6.83%	-5.45%	10/9/2025 (Estimated)

Latest RNAC, PHVS, GPCR, and TLRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	PHVS Pharvaris	-$0.87	-$0.94	-$0.07	-$0.94	N/A	N/A
8/7/2025	Q2 2025	RNAC Cartesian Therapeutics	-$0.76	$0.50	+$1.26	$0.50	$0.77 million	$0.30 million
8/6/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	-$0.36	-$0.08	-$0.36	N/A	N/A
7/28/2025	Q4 2025	TLRY Tilray Brands	-$0.03	$0.02	+$0.05	-$1.30	$250.41 million	$224.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GPCR Structure Therapeutics	N/A	20.48	20.48
PHVS Pharvaris	N/A	8.33	8.33
RNAC Cartesian Therapeutics	N/A	13.33	13.33
TLRY Tilray Brands	0.20	2.46	1.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GPCR Structure Therapeutics	91.78%
PHVS Pharvaris	N/A
RNAC Cartesian Therapeutics	86.95%
TLRY Tilray Brands	9.35%

Insider Ownership

Company	Insider Ownership
GPCR Structure Therapeutics	5.60%
PHVS Pharvaris	N/A
RNAC Cartesian Therapeutics	60.30%
TLRY Tilray Brands	0.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GPCR Structure Therapeutics	136	57.60 million	54.37 million	Optionable
PHVS Pharvaris	30	52.29 million	N/A	Not Optionable
RNAC Cartesian Therapeutics	64	26.00 million	10.32 million	Optionable
TLRY Tilray Brands	2,842	1.10 billion	1.09 billion	Optionable

RNAC, PHVS, GPCR, and TLRY Headlines

Recent News About These Companies

Tilray Brands (NASDAQ:TLRY) Trading 3.2% Higher After Analyst Upgrade

August 27 at 2:29 AM | americanbankingnews.com

Tilray Brands (NASDAQ:TLRY) Shares Gap Up on Analyst Upgrade

August 27 at 2:50 AM | americanbankingnews.com

Why Tilray (TLRY) Stock Is Up Today

August 26 at 5:05 PM | msn.com

US cannabis stocks rally as Trump backs rescheduling

August 26 at 4:04 PM | proactiveinvestors.com

Tilray Brands (TLRY) Jumps 23% as Analyst Goes Bullish on Cannabis Prospects

August 26 at 1:32 PM | insidermonkey.com

Here's why Tilray stock price is soaring and why it may crash soon

August 26 at 1:05 PM | invezz.comI

Tilray Brands (NASDAQ:TLRY) Trading Up 18.7% on Analyst Upgrade

August 26 at 11:13 AM | marketbeat.com

Tilray Brands shares gain as analysts boost price target on cannabis rescheduling optimism

August 26 at 11:13 AM | proactiveinvestors.com

Tilray Brands (NASDAQ:TLRY) Shares Gap Up After Analyst Upgrade

August 26 at 10:52 AM | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Given New $2.00 Price Target at Jefferies Financial Group

August 26 at 10:35 AM | marketbeat.com

Top Canadian Marijuana Stocks to Watch in 2025 : Industry Growth and Legalization Updates

August 26 at 10:00 AM | marijuanastocks.comM

Tilray Brands: Path To 5x Growth For TLRY Stock

August 26 at 10:00 AM | forbes.com

Tilray Brands, Inc. (NASDAQ:TLRY) Receives $1.92 Consensus PT from Analysts

August 26 at 2:54 AM | americanbankingnews.com

Tilray Brands Sees Unusually High Options Volume (NASDAQ:TLRY)

August 26 at 2:27 AM | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says

August 26 at 2:05 AM | americanbankingnews.com

Tilray Brands (NASDAQ:TLRY) Shares Up 18.7% Following Analyst Upgrade

August 26 at 2:23 AM | americanbankingnews.com

Tilray Brands (NASDAQ:TLRY) Trading Up 2.3% - What's Next?

August 23, 2025 | marketbeat.com

Tilray Brands, Inc. (NASDAQ:TLRY) Given Average Recommendation of "Hold" by Analysts

August 23, 2025 | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Stock Price Up 3.3% - Here's What Happened

August 22, 2025 | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Trading Down 3.3% - Time to Sell?

August 21, 2025 | marketbeat.com

Tilray's High Hopes: The Catalyst Driving Cannabis Stocks

...

August 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RNAC, PHVS, GPCR, and TLRY Company Descriptions

Structure Therapeutics NASDAQ:GPCR

$18.82 +0.25 (+1.35%)

Closing price 08/26/2025 04:00 PM Eastern

Extended Trading

$19.14 +0.32 (+1.72%)

As of 07:16 AM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Pharvaris NASDAQ:PHVS

$24.00 +0.35 (+1.48%)

Closing price 08/26/2025 04:00 PM Eastern

Extended Trading

$23.98 -0.02 (-0.06%)

As of 08/26/2025 04:12 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Cartesian Therapeutics NASDAQ:RNAC

$10.78 -0.47 (-4.18%)

Closing price 08/26/2025 04:00 PM Eastern

Extended Trading

$10.78 0.00 (-0.05%)

As of 08/26/2025 07:29 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Tilray Brands NASDAQ:TLRY

$1.45 +0.06 (+4.32%)

Closing price 08/26/2025 04:00 PM Eastern

Extended Trading

$1.42 -0.03 (-2.41%)

As of 08:01 AM Eastern

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time